MAIA Biotechnology (MAIA) Liabilities and Shareholders Equity (2021 - 2026)

MAIA Biotechnology (MAIA) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $35.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 197.71% year-over-year to $35.3 million; the TTM figure through Mar 2026 stood at $67.9 million (up 56.77% YoY), while the FY2025 annual figure was $9.7 million, down 4.44% from the prior year.
• Liabilities and Shareholders Equity advanced to $35.3 million in Q1 2026 per MAIA's latest filing, from $9.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $35.3 million in Q1 2026 and bottomed at $7.0 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $11.9 million across 5 years, with a median of $10.2 million in 2023.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity tumbled 52.64% — and 2026, when it soared 197.71%.
• MAIA Biotechnology's Liabilities and Shareholders Equity stood at $12.0 million in 2022, then sank by 37.06% to $7.6 million in 2023, then surged by 34.21% to $10.2 million in 2024, then decreased by 4.44% to $9.7 million in 2025, then surged by 263.98% to $35.3 million in 2026.
• Business Quant data shows MAIA's Liabilities and Shareholders Equity at $35.3 million in Q1 2026, $9.7 million in Q4 2025, and $11.8 million in Q3 2025.